Infliximab's Pharmacokinetic and Pharmacodynamic Effects on Paediatric Ulcerative Colitis Patients
Received Date: Nov 22, 2022 / Accepted Date: Dec 19, 2022 / Published Date: Dec 20, 2022
Abstract
The colon is largely impacted by the chronic gastrointestinal inflammatory illness known as ulcerative colitis (UC). Patients with UC experience chronic inflammation of the colon's surface mucosa, crypt epithelium, and/or submucosa, which results in bloody diarrhoea, stomach pain, weight loss, and fever. Although UC symptoms are similar in both adults and children, pediatric-onset UC is more usually associated with acute severe exacerbations because it tends to be more severe than in adult patients. This study's primary goal is to evaluate infliximab pharmacokinetics in children with ulcerative colitis (UC).
Citation: Joseph S (2022) Infliximab's Pharmacokinetic and Pharmacodynamic Effects on Paediatric Ulcerative Colitis Patients. J Pharmacokinet Exp Ther 6: 160. Doi: 10.4172/jpet.1000160
Copyright: © 2022 Joseph S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
黑料网 Journals
Article Tools
Article Usage
- Total views: 853
- [From(publication date): 0-2022 - Nov 23, 2024]
- Breakdown by view type
- HTML page views: 676
- PDF downloads: 177
